23.94
전일 마감가:
$23.60
열려 있는:
$22.04
하루 거래량:
5.02M
Relative Volume:
1.08
시가총액:
$2.76B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-25.74
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
+11.25%
1개월 성능:
-19.75%
6개월 성능:
-62.95%
1년 성능:
-63.98%
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VKTX
Viking Therapeutics Inc
|
23.94 | 2.76B | 0 | -99.15M | -74.25M | -0.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-08 | 개시 | Goldman | Neutral |
2025-02-13 | 개시 | Scotiabank | Sector Outperform |
2025-02-07 | 개시 | Citigroup | Neutral |
2024-12-02 | 개시 | Piper Sandler | Overweight |
2024-11-22 | 개시 | B. Riley Securities | Buy |
2024-11-04 | 재확인 | H.C. Wainwright | Buy |
2024-09-11 | 개시 | JP Morgan | Overweight |
2024-06-27 | 개시 | Morgan Stanley | Overweight |
2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2024-03-26 | 재확인 | Oppenheimer | Outperform |
2024-03-07 | 개시 | Jefferies | Buy |
2024-02-28 | 재확인 | Oppenheimer | Outperform |
2023-05-31 | 재개 | ROTH MKM | Buy |
2023-03-28 | 재확인 | Maxim Group | Buy |
2023-03-17 | 개시 | Stifel | Buy |
2021-07-29 | 재개 | BTIG Research | Buy |
2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2020-06-05 | 개시 | BMO Capital Markets | Outperform |
2020-05-05 | 개시 | Chardan Capital Markets | Buy |
2020-05-01 | 개시 | BTIG Research | Buy |
2019-07-16 | 개시 | Oppenheimer | Outperform |
2019-06-25 | 개시 | Stifel | Buy |
2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2019-03-14 | 재확인 | Maxim Group | Buy |
2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
2018-12-12 | 개시 | B. Riley FBR | Buy |
2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2018-09-18 | 재확인 | H.C. Wainwright | Buy |
2018-09-18 | 재확인 | Maxim Group | Buy |
2018-09-18 | 재확인 | Raymond James | Outperform |
2018-07-20 | 개시 | SunTrust | Buy |
2018-06-28 | 개시 | Raymond James | Outperform |
2018-06-01 | 재확인 | Laidlaw | Buy |
2018-05-31 | 재확인 | Maxim Group | Buy |
2018-03-26 | 재개 | H.C. Wainwright | Buy |
2017-11-28 | 재확인 | Maxim Group | Buy |
2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance
H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data - Yahoo Finance
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide - Yahoo Finance
Viking Therapeutics (VKTX) Gains Attention with Promising Diabetes Treatment | LLY Stock News - GuruFocus
2 Stocks Down by 25% or More This Year to Buy and Hold - Yahoo Finance
Viking Therapeutics: A Lot More Compelling After The MeltdownInitiating Cautious Buy (Rating Upgrade) - Seeking Alpha
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Viking Therapeutics (VKTX) to Announce Q1 2025 Financial Results - GuruFocus
Viking Therapeutics Inc (VKTX) Stock Price, Trades & News - GuruFocus
Viking Therapeutics (VKTX) Shares Decline Following Eli Lilly's Phase 3 Results | LLY Stock News - GuruFocus
Viking Therapeutics slips after Eli Lilly reports orforglipron trial results - TipRanks
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Quantisnow
Viking Therapeutics to Report Financial Results for First Quarte - GuruFocus
Viking Therapeutics Sets Q1 Earnings Date: Key Updates Expected on Metabolic Drug Pipeline - Stock Titan
Viking Therapeutics Stock Pops But Struggles to Hold Gains - MarketBeat
Viking Therapeutics Stock Pops But Struggles To Hold Gains - Barchart.com
Viking Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VKTX - Benzinga
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market - Seeking Alpha
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? - MSN
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Zacks Investment Research
Viking Therapeutics (VKTX) Surges as Pfizer Halts Obesity Drug - GuruFocus
Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? - MSN
Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4) - Quantisnow
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg.com
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Globe and Mail
Pfizer's $130B Weight-Loss Dream Just Collapsed - Yahoo Finance
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug - Schaeffer's Investment Research
Viking Therapeutics shares surge on Pfizer’s drug discontinuation By Investing.com - Investing.com India
Viking Therapeutics shares surge on Pfizer’s drug discontinuation - Investing.com
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years? - Yahoo
Viking Therapeutics stock hits 52-week low at $20.26 - Investing.com Australia
Viking Therapeutics stock hits 52-week low at $20.26 By Investing.com - Investing.com South Africa
Goldman Sachs Initiates Coverage of Viking Therapeutics (VKTX) with Neutral Recommendation - Nasdaq
Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4) - Quantisnow
Goldman Sachs Initiates Coverage on Viking Therapeutics (VKTX) w - GuruFocus
Viking Therapeutics draws Neutral rating at Goldman Sachs on competitive headwinds - Seeking Alpha
Goldman initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target - MarketScreener
Goldman Sachs sets Viking Therapeutics stock at Neutral By Investing.com - Investing.com Canada
The Smartest Biotech Stocks to Buy With $50 - AOL.com
When the Price of (VKTX) Talks, People Listen - news.stocktradersdaily.com
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow
Viking therapeutics director Rouan buys $29,942 in stock By Investing.com - Investing.com Canada
Viking therapeutics director Rouan buys $29,942 in stock - Investing.com India
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):